中文 | English
Return
Total: 1290 , 1/129
Show Home Prev Next End page: GO
MeSH:(Antineoplastic Agents/therapeutic use*)

2.Procedures for application of the extended dosing after antitumor drug clinical trials.

Feng YANG ; Jianfu HENG ; Yi LIU ; Qi TANG ; Kunyan LI

Journal of Central South University(Medical Sciences) 2023;48(4):508-515

3.Effect of brentuximab vedotin combined with chlormethine hydrochloride on the treatment of 6 patients with relapsed and refractory Hodgkin lymphoma.

Zhigang CAO ; Zhihong WANG ; Junzhong SUN ; Chaojin PENG ; Shaomei FENG ; Xiaoyan ZHOU ; Qingming YANG

Chinese Journal of Hematology 2015;36(7):575-577

5.Expert consensus on the clinical application of antibody drug conjugates in the treatment of malignant tumors (2020 Edition).

Chinese Journal of Oncology 2021;43(1):78-91

6.Chinese Medicine Amygdalin and β-Glucosidase Combined with Antibody Enzymatic Prodrug System As A Feasible Antitumor Therapy.

Yun-Long LI ; Qiao-Xing LI ; Rui-Jiang LIU ; Xiang-Qian SHEN

Chinese journal of integrative medicine 2018;24(3):237-240

7.Current Progress and Future Developments of Antibody Drug Conjugates 
in Lung Cancer.

Yixiang ZHU ; Zhijie WANG

Chinese Journal of Lung Cancer 2022;25(7):468-476

9.Evaluation considerations for using surrogate endpoints in anticancer clinical trials.

Yuan Yuan SONG ; Ling TANG ; Lin XIA ; Rui Min HAO ; Zhi Min YANG

Chinese Journal of Oncology 2022;44(11):1155-1159

10.Application of MIDD in Clinical Research of Antitumor Drugs.

Mengyang YU ; Hongyun WANG

Chinese Journal of Lung Cancer 2022;25(7):487-492

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 1290 , 1/129 Show Home Prev Next End page: GO